Redefining advances in modern oncology research
Abstract
Keywords
Full Text:
PDFReferences
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674. doi: 10.1016/j.cell.2011.02.013.
DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 2016; 2(5): e1600200. doi: 10.1126/sciadv.1600200.
Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, et al. Targeting cancer metabolism: Dietary and pharmacologic interventions. Cancer Discov 2016; 6(12): 1315-1333. doi: 10.1158/2159-8290.CD-16-0615.
Ledford H. End of cancer-genome project prompts rethink. Nature 2015; 517(7533): 128-129. doi: 10.1038/517128a.
The Cancer Genome Atlas [Internet]. National Institutes of Health (US); [updated 2017 Feb 2; cited 2017 Feb 15]. Available from: https://cancergenome.nih.gov.
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375(22): 2154-2164. doi: 10.1056/NEJMoa1611310.
Wheler JJ, Janku F, Naing A, Li Y, Stephen B, et al. Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res 2016; 76(13): 3690-3701. doi: 10.1158/0008-5472.CAN-15-3043.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016; 375(19): 1845-1855. doi: 10.1056/NEJMoa1611299.
Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016; 315(15): 1600-1609. doi: 10.1001/jama.2016.4059.
Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387(10027): 1540-1550. doi: 10.1016/S0140-6736(15)01281-7.
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet Oncol 2017; 18(2): 212-220. doi: 10.1016/S1470-2045(17)30007-4.
U.S. Food and Drug Administration [Internet]. Silver Spring (MD): [updated 2017 Feb 2; cited 2017 Feb 15]. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm.
Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, et al. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05): 1-30.
Wojtowicz ME, Dunn BK, Umar A. Immunologic approaches to cancer prevention-current status, challenges, and future perspectives. Semin Oncol 2016; 43(1): 161-172. doi: 10.1053/j.seminoncol.2015.11.001.
Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res (Phila) 2016; 9(1): 2-10. doi: 10.1158/1940-6207.CAPR-15-0406.
Epstein AS, Prigerson HG, O'Reilly EM, Maciejewski PK. Discussions of life expectancy and changes in illness understanding in patients with advanced cancer. J Clin Oncol 2016; 34(20): 2398-2403. doi: 10.1200/JCO.2015.63.6696.
Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016; 6(5): 479-491. doi: 10.1158/2159-8290.CD-15-1483.
Lebofsky R, Decraene C, Bernard V, Kamal M, Blin A, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015; 9(4): 783-790. doi: 10.1016/j.molonc.2014.12.003.
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497(7447): 108-112. doi: 10.1038/nature12065.
Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 2015; 90(3): 509-515. doi: 10.1016/j.lungcan.2015.10.004.
U.S. Food and Drug Administration. Silver Spring (MD): [updated 2017 Feb 2; cited 2017 Feb 15]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf15/P150047a.pdf.
Grossman RL, Abel B, Angiuoli S, Barrett JC, Bassett D, et al. Collaborating to compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium. Clin Pharmacol Ther 2017. doi: 10.1002/cpt.666.
McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7(2): 418-419. doi: 10.3945/an.116.012211.
Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 2015; 35 Suppl:S276-304. doi: 10.1016/j.semcancer.2015.09.007.
DOI: http://dx.doi.org/10.30564/amor.v3i1.97
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Kwong-Kwok Wong

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.